最大值
药代动力学
伊曲康唑
医学
单中心
药理学
耐受性
不利影响
活性代谢物
CYP3A型
口服
内科学
皮肤病科
新陈代谢
细胞色素P450
抗真菌
作者
Yunzhe Huang,Yuanwei Jia,Xinyan Chen,Changmao Wang,Yaqin Wang,Minhui Wang,Peng Wu,Jie Shen
标识
DOI:10.1080/17425255.2023.2292112
摘要
Famitinib, the novel oral multitargeting tyrosine kinase inhibitor, was developed for treatment of patients with advanced solid cancer. This investigation assessed the pharmacokinetic (PK) effects of itraconazole, an officially recommended CYP3A4 strong inhibitor, on famitinib and its metabolite (SHR116637).A single-center, single-arm, open-label, and fixed sequence study was conducted in 22 healthy subjects. Famitinib was administered as a single oral 15 mg on Day1. Itraconazole 200 mg once daily was given from Day12 to Day24, concomitantly with famitinib on Day15 and for follow-up during Day30 to Day32. Blood sampling followed each famitinib dosage for PK analysis of famitinib and SHR116637. Safety and tolerability were also assessed throughout the treatment.Cmax, AUC0-t and AUC0-∞ were raised by 40.6%, 77.7% and 81.6%, respectively, and t1/2 was prolonged from 36.08 hours to 48.24 hours for famitinib. In contrast, Cmax, AUC0-t and AUC0-∞ were reduced by 63.5%, 42.6%, and 39.0%, respectively, for SHR116637. Eight (36.4%) subjects reported seventeen treatments that emerged adverse events (all grade 1-2 in severity) all recovered at follow-up period.Single oral dose of 15 mg famitinib and co-therapy with 200 mg intraconazole were safe and well tolerated in healthy subjects. Famitinib should be avoided in conjunction with strong CYP3A inhibitors if possible.This trial was registered at http://www.chinadrugtrials.org.cn/index.html. (Registration number: CTR20201824.).
科研通智能强力驱动
Strongly Powered by AbleSci AI